Cargando…

Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding

Pulmonary arterial hypertension (PAH) is a progressive disorder characterized by remodeling of the pulmonary vasculature and a rise in right ventricular (RV) afterload. The increased RV afterload leads to right ventricular failure (RVF) which is the reason for the high morbidity and mortality in PAH...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rai, Nabham, Veeroju, Swathi, Schymura, Yves, Janssen, Wiebke, Wietelmann, Astrid, Kojonazarov, Baktybek, Weissmann, Norbert, Stasch, Johannes-Peter, Ghofrani, Hossein Ardeschir, Seeger, Werner, Schermuly, Ralph Theo, Novoyatleva, Tatyana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817266/ https://www.ncbi.nlm.nih.gov/pubmed/29511676 http://dx.doi.org/10.1155/2018/3293584

Ejemplares similares

Response to: Comment on “Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding”
por: Rai, Nabham, et al.
Publicado: (2018)

Effects of riociguat in severe experimental pulmonary hypertension
por: Kojonazarov, Baktybek, et al.
Publicado: (2011)

Therapeutic Potential of Regorafenib—A Multikinase Inhibitor in Pulmonary Hypertension
por: Veeroju, Swathi, et al.
Publicado: (2021)

Targeting peptidyl-prolyl isomerase 1 in experimental pulmonary arterial hypertension
por: Rai, Nabham, et al.
Publicado: (2022)

The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats
por: Lang, Michaela, et al.
Publicado: (2011)

The Soluble Guanylate Cyclase Stimulator Riociguat Ameliorates Pulmonary Hypertension Induced by Hypoxia and SU5416 in Rats
por: Lang, Michaela, et al.
Publicado: (2012)

5-HT2B Receptor Antagonists Inhibit Fibrosis and Protect from RV Heart Failure
por: Janssen, Wiebke, et al.
Publicado: (2015)

Effect of p53 activation on experimental right ventricular hypertrophy
por: Veeroju, Swathi, et al.
Publicado: (2020)

Improvement of right heart structure and function by BAY 41-8543 in pulmonary artery banded mice
por: Janssen, Wiebke, et al.
Publicado: (2011)

Correction: Improvement of right heart structure and function by BAY41-8543 in pulmonary artery banded mice
por: Janssen, Wiebke, et al.
Publicado: (2011)

Retraction: Nitric Oxide Synthase 2 Induction Promotes Right Ventricular Fibrosis
por: Boehm, Mario, et al.
Publicado: (2022)

IRAG1 Deficient Mice Develop PKG1β Dependent Pulmonary Hypertension
por: Biswas, Siladitta, et al.
Publicado: (2020)

Reply to Bogaard et al.: Emphysema Is—at the Most—Only a Mild Phenotype in the Sugen/Hypoxia Rat Model of Pulmonary Arterial Hypertension
por: Kojonazarov, Baktybek, et al.
Publicado: (2019)

Pressure overload leads to an increased accumulation and activity of mast cells in the right ventricle
por: Luitel, Himal, et al.
Publicado: (2017)

A novel noninvasive method for estimating right ventricular systolic pressure in rodents with pulmonary artery banding
por: Kojonazarov, Baktybek, et al.
Publicado: (2023)

Deficiency of Axl aggravates pulmonary arterial hypertension via BMPR2
por: Novoyatleva, Tatyana, et al.
Publicado: (2021)

Author Correction: Deficiency of Axl aggravates pulmonary arterial hypertension via BMPR2
por: Novoyatleva, Tatyana, et al.
Publicado: (2022)

Genetic Deficiency and Pharmacological Stabilization of Mast Cells Ameliorate Pressure Overload-Induced Maladaptive Right Ventricular Remodeling in Mice
por: Sydykov, Akylbek, et al.
Publicado: (2020)

Genetic Delivery and Gene Therapy in Pulmonary Hypertension
por: Rai, Nabham, et al.
Publicado: (2021)

Effects of Multikinase inhibitors on pressure overload-induced right ventricular remodelling
por: Kojonazarov, Baktybek, et al.
Publicado: (2013)

Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension
por: Boehm, Mario, et al.
Publicado: (2018)

Correction to: Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension
por: Boehm, Mario, et al.
Publicado: (2022)

Chronic intratracheal application of the soluble guanylyl cyclase stimulator BAY 41-8543 ameliorates experimental pulmonary hypertension
por: Amirjanians, Matthieu, et al.
Publicado: (2017)

Comment on “Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding”
por: Andersen, Asger
Publicado: (2018)

Deletion of Fn14 receptor protects from right heart fibrosis and dysfunction
por: Novoyatleva, Tatyana, et al.
Publicado: (2013)

Targeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension
por: Weiss, Astrid, et al.
Publicado: (2019)

Protection against pressure overload-induced right heart failure by uncoupling protein 2 silencing
por: Esfandiary, Azadeh, et al.
Publicado: (2019)

Therapeutic efficacy of TBC3711 in monocrotaline-induced pulmonary hypertension
por: Kosanovic, Djuro, et al.
Publicado: (2011)

Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors
por: Schermuly, Ralph Theo, et al.
Publicado: (2005)

Developmental vascular remodeling defects and postnatal kidney failure in mice lacking Gpr116 (Adgrf5) and Eltd1 (Adgrl4)
por: Lu, Shun, et al.
Publicado: (2017)

Cigarette Smoke-Induced Emphysema and Pulmonary Hypertension Can Be Prevented by Phosphodiesterase 4 and 5 Inhibition in Mice
por: Seimetz, Michael, et al.
Publicado: (2015)

Riociguat for pulmonary arterial hypertension associated with congenital heart disease
por: Rosenkranz, Stephan, et al.
Publicado: (2015)

Riociguat versus sildenafil on hypoxic pulmonary vasoconstriction and ventilation/perfusion matching
por: Chamorro, Virginia, et al.
Publicado: (2018)

Phosphodiesterase 10A Upregulation Contributes to Pulmonary Vascular Remodeling
por: Tian, Xia, et al.
Publicado: (2011)

Yarsagumba is a Promising Therapeutic Option for Treatment of Pulmonary Hypertension due to the Potent Anti-Proliferative and Vasorelaxant Properties
por: Luitel, Himal, et al.
Publicado: (2020)

Switching to riociguat: a potential treatment strategy for the management of CTEPH and PAH
por: Benza, Raymond L., et al.
Publicado: (2020)

sGC activators and stimulators attenuate ischemia/reperfusion injury of the lung
por: Egemnazarov, Bakytbek, et al.
Publicado: (2009)

Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration
por: Pullamsetti, Soni, et al.
Publicado: (2005)

Effect of riociguat on pulmonary arterial compliance in the PATENT and CHEST studies
por: Thenappan, Thenappan, et al.
Publicado: (2020)

FHL-1 is not involved in pressure overload-induced maladaptive right ventricular remodeling and dysfunction
por: Veith, Christine, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_h93sdns0nk1dmokvqq0ealrk3t